Abstract 1070P
Background
Immune checkpoint inhibitors (ICIs) have yielded promising results in the treatment of cancer patients with central nervous system (CNS) metastases. However, due to a dearth of clinical research, it is necessary to further elucidate the side effects of ICIs in patients with CNS metastases.
Methods
We identified patients with CNS metastases treated with ICIs from Q1 2013 to Q2 2022 by scrutinizing the FDA Adverse Event Reporting System (FAERS) database. Following removal of duplicate data, the study collected 511 cases. Subsequently, disproportionality analysis was performed. Risk factors were explored using univariate and multivariate logistic regression. Moreover, the influence of clinical factors on the time to onset of adverse reactions was examined.
Results
The study revealed a higher susceptibility to psychiatric complications, including confusion state, insomnia, mania, and memory impairment, following ICIs treatment in CNS metastasis patients. Furthermore, rare but severe retinal detachment may arise due to anti-PDL1 drug usage, whereas co-administration of anti-PD1 and anti-CTLA4 drugs may produce nephrotoxicity concerns. Multivariate logistic regression analysis demonstrated that the combined therapy of anti-PD1+anti-CTLA4 therapy was an independent risk factor for adverse nephrotoxic reactions in CNS metastasis patients (OR: 2.75, 95%CI: 1.37-5.46, P<0.05). The onset time of complications differed depending on the immunotherapeutic strategy. Anti-PD-L1 therapy had a later onset time of complications (Median: 67 days, IQR: 28.75-114.25) compared to that of anti-PD1 (Median: 33 days, IQR: 10-90) and anti-CTLA4 therapy (Median: 29 days, IQR:10.5-52.5), respectively. Furthermore, our study indicated that younger patients exhibited a higher probability of fatal complications (OR: 0.97, 95%CI: 0.95-0.99, P=0.02) and experienced a shorter time to onset of complications (r=2.27, P=0.007).
Conclusions
This study employed a massive database to investigate the spectrum of adverse reactions resulting from ICIs therapy administered to CNS metastasis patients, thereby providing vigilance data for broader clinical applications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peng Luo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1027P - An open-label, multicenter, phase I/II study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors (Part A of GII-101-P101; KEYNOTE-B59)
Presenter: Byoung Chul Cho
Session: Poster session 19
1028P - Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
Presenter: Daphne Day
Session: Poster session 19
1029P - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Presenter: Anthony Olszanski
Session: Poster session 19
1030P - Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1031P - ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1032P - A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer
Presenter: Zhi Peng
Session: Poster session 19
1033P - First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors
Presenter: Aung Naing
Session: Poster session 19
1034P - Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
Presenter: Alexander Starodub
Session: Poster session 19
1035P - Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors
Presenter: Ho Yeong Lim
Session: Poster session 19
1036P - A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
Presenter: Junli Xue
Session: Poster session 19